News Releases Joni Henderson 9/30/24 Joni Henderson 9/30/24 C2N Diagnostics Receives $15 Million Program Related Investment from GHR Foundation to Develop Tau Tangle Pathology Test for Diagnosing, Staging Alzheimer’s Disease Read More Joni Henderson 9/25/24 Joni Henderson 9/25/24 C2N Receives Funding from Diagnostics Accelerator to Develop a Decentralized Clinical Mass Spectrometry Solution to Enable High-Performance Alzheimer’s Disease Testing Worldwide Read More Joni Henderson 8/6/24 Joni Henderson 8/6/24 C2N Diagnostics and Unilabs Announce Global Partnership, Bringing Together Innovation Leaders in Diagnostics and Laboratory Medicine to Advance Brain Health Read More Joni Henderson 7/28/24 Joni Henderson 7/28/24 JAMA Publishes Landmark Clinical Study Showing C2N Diagnostics’ PrecivityAD2™ Blood Test Markedly Improves Accuracy of AD Diagnosis in Both Primary Care and Specialized Memory Care Read More Joni Henderson 7/2/24 Joni Henderson 7/2/24 C2N Diagnostics Says FDA’s Approval of Donanemab Highlights Its Role in Helping to Determine Alzheimer’s Disease Pathology Read More Joni Henderson 6/26/24 Joni Henderson 6/26/24 C2N’s Precivity™ Tests are Now Offered Through Mayo Clinic Laboratories Read More Joni Henderson 4/26/24 Joni Henderson 4/26/24 C₂N Diagnostics Expands Into Japan Through Mediford Corporation Partnership With Precivity™ Blood Testing forAlzheimer’s Disease and Brain Research Market Read More Joni Henderson 3/31/24 Joni Henderson 3/31/24 Study Finds C₂N Diagnostics’ PrecivityAD® Blood Test Provides Opportunities for Robust Cost Savings in the Evaluation of Patients with Cognitive Impairment Read More Joni Henderson 3/18/24 Joni Henderson 3/18/24 New Research Shows the PrecivityAD2™ Blood Test Has High Accuracy Compared to Amyloid PET Scans in Individuals with Cognitive Impairment Read More Joni Henderson 3/6/24 Joni Henderson 3/6/24 C₂N Diagnostics, LLC Announces Investment From Eisai Inc. Read More Joni Henderson 11/16/23 Joni Henderson 11/16/23 Researchers Identify New Cost Savings and Accuracy of C₂N Diagnostics’ Blood Tests to Enable Healthcare Providers to Better Identify Alzheimer’s Disease Read More Joni Henderson 11/7/23 Joni Henderson 11/7/23 New Research Shows High Accuracy of Precivity™ Blood Biomarkers in the Evaluation of Brain Amyloid in Pre-Clinical Alzheimer's Disease Read More Joni Henderson 10/25/23 Joni Henderson 10/25/23 C₂N Diagnostics Introduces Next-Generation Fluid Biomarker to the Field of Alzheimer’s Disease: Test to Help Researchers Track Neurofibrillary “Tau” Tangle Pathology Read More Joni Henderson 9/21/23 Joni Henderson 9/21/23 On World Alzheimer’s Day, C₂N Diagnostics’ PrecivityAD2™ Blood Test Expands Reach Read More Joni Henderson 8/17/23 Joni Henderson 8/17/23 C₂N Diagnostics Releases the PrecivityAD2™ Blood Test for Clinical Care, A Robust Assay with High Concordance to Amyloid PET and CSF Read More Joni Henderson 8/8/23 Joni Henderson 8/8/23 Real-World Evidence Shows Healthcare Providers Use C₂N Diagnostics’ PrecivityAD® Blood Test to Help Affirm Alzheimer’s Disease Diagnosis and Change Drug Treatment Decisions Read More Joni Henderson 8/2/23 Joni Henderson 8/2/23 Alzheimer’s Disease Community Benefits as C₂N Diagnostics’ Precivity™-Related Blood Biomarkers Demonstrate Robust Effectiveness, Set New Performance Standard Read More Tim West 7/11/23 Tim West 7/11/23 C₂N Diagnostics, Used in Clinical Trials for LEQEMBI™ for Alzheimer’s Disease Treatment, Is Poised to Support Medical Community in Next Steps Read More Joni Henderson 4/24/23 Joni Henderson 4/24/23 C₂N Diagnostics, Building on Recent Achievements, Bolsters Executive Team as It Prepares for Commercial Expansion Read More Joni Henderson 4/4/23 Joni Henderson 4/4/23 C₂N Diagnostics’ Precivity-Related Blood Biomarkers Shown to Improve Diagnostic Accuracy and Future Risk Prediction of Alzheimer’s Disease in Two Studies Presented at AD/PD 2023 Read More Older Posts
Joni Henderson 9/30/24 Joni Henderson 9/30/24 C2N Diagnostics Receives $15 Million Program Related Investment from GHR Foundation to Develop Tau Tangle Pathology Test for Diagnosing, Staging Alzheimer’s Disease Read More
Joni Henderson 9/25/24 Joni Henderson 9/25/24 C2N Receives Funding from Diagnostics Accelerator to Develop a Decentralized Clinical Mass Spectrometry Solution to Enable High-Performance Alzheimer’s Disease Testing Worldwide Read More
Joni Henderson 8/6/24 Joni Henderson 8/6/24 C2N Diagnostics and Unilabs Announce Global Partnership, Bringing Together Innovation Leaders in Diagnostics and Laboratory Medicine to Advance Brain Health Read More
Joni Henderson 7/28/24 Joni Henderson 7/28/24 JAMA Publishes Landmark Clinical Study Showing C2N Diagnostics’ PrecivityAD2™ Blood Test Markedly Improves Accuracy of AD Diagnosis in Both Primary Care and Specialized Memory Care Read More
Joni Henderson 7/2/24 Joni Henderson 7/2/24 C2N Diagnostics Says FDA’s Approval of Donanemab Highlights Its Role in Helping to Determine Alzheimer’s Disease Pathology Read More
Joni Henderson 6/26/24 Joni Henderson 6/26/24 C2N’s Precivity™ Tests are Now Offered Through Mayo Clinic Laboratories Read More
Joni Henderson 4/26/24 Joni Henderson 4/26/24 C₂N Diagnostics Expands Into Japan Through Mediford Corporation Partnership With Precivity™ Blood Testing forAlzheimer’s Disease and Brain Research Market Read More
Joni Henderson 3/31/24 Joni Henderson 3/31/24 Study Finds C₂N Diagnostics’ PrecivityAD® Blood Test Provides Opportunities for Robust Cost Savings in the Evaluation of Patients with Cognitive Impairment Read More
Joni Henderson 3/18/24 Joni Henderson 3/18/24 New Research Shows the PrecivityAD2™ Blood Test Has High Accuracy Compared to Amyloid PET Scans in Individuals with Cognitive Impairment Read More
Joni Henderson 3/6/24 Joni Henderson 3/6/24 C₂N Diagnostics, LLC Announces Investment From Eisai Inc. Read More
Joni Henderson 11/16/23 Joni Henderson 11/16/23 Researchers Identify New Cost Savings and Accuracy of C₂N Diagnostics’ Blood Tests to Enable Healthcare Providers to Better Identify Alzheimer’s Disease Read More
Joni Henderson 11/7/23 Joni Henderson 11/7/23 New Research Shows High Accuracy of Precivity™ Blood Biomarkers in the Evaluation of Brain Amyloid in Pre-Clinical Alzheimer's Disease Read More
Joni Henderson 10/25/23 Joni Henderson 10/25/23 C₂N Diagnostics Introduces Next-Generation Fluid Biomarker to the Field of Alzheimer’s Disease: Test to Help Researchers Track Neurofibrillary “Tau” Tangle Pathology Read More
Joni Henderson 9/21/23 Joni Henderson 9/21/23 On World Alzheimer’s Day, C₂N Diagnostics’ PrecivityAD2™ Blood Test Expands Reach Read More
Joni Henderson 8/17/23 Joni Henderson 8/17/23 C₂N Diagnostics Releases the PrecivityAD2™ Blood Test for Clinical Care, A Robust Assay with High Concordance to Amyloid PET and CSF Read More
Joni Henderson 8/8/23 Joni Henderson 8/8/23 Real-World Evidence Shows Healthcare Providers Use C₂N Diagnostics’ PrecivityAD® Blood Test to Help Affirm Alzheimer’s Disease Diagnosis and Change Drug Treatment Decisions Read More
Joni Henderson 8/2/23 Joni Henderson 8/2/23 Alzheimer’s Disease Community Benefits as C₂N Diagnostics’ Precivity™-Related Blood Biomarkers Demonstrate Robust Effectiveness, Set New Performance Standard Read More
Tim West 7/11/23 Tim West 7/11/23 C₂N Diagnostics, Used in Clinical Trials for LEQEMBI™ for Alzheimer’s Disease Treatment, Is Poised to Support Medical Community in Next Steps Read More
Joni Henderson 4/24/23 Joni Henderson 4/24/23 C₂N Diagnostics, Building on Recent Achievements, Bolsters Executive Team as It Prepares for Commercial Expansion Read More
Joni Henderson 4/4/23 Joni Henderson 4/4/23 C₂N Diagnostics’ Precivity-Related Blood Biomarkers Shown to Improve Diagnostic Accuracy and Future Risk Prediction of Alzheimer’s Disease in Two Studies Presented at AD/PD 2023 Read More
